You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Litigation Details for ePlus, Inc. v. Lawson Software, Inc. (E.D. Va. 2009)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in ePlus, Inc. v. Lawson Software, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis for ePlus, Inc. v. Lawson Software, Inc. | 3:09-cv-00620

Last updated: February 27, 2026

Case Overview

ePlus, Inc. filed a patent infringement lawsuit against Lawson Software, Inc. in the District of Delaware. The case (D. Del., 3:09-cv-00620) centers on allegations that Lawson infringed upon ePlus’s patents related to license management and software compliance systems. The proceedings spanned multiple years, involving claims construction disputes, summary judgment motions, and trial.

Timeline and Key Procedural Milestones

  • Filing and Pleadings: ePlus filed suit in July 2009, asserting infringement of U.S. Patent No. 6,611,278 (the '278 patent) and U.S. Patent No. 7,344,233 (the '233 patent).

  • Claims Construction: The court adopted a Markman order in 2010, defining terms crucial to patent scope, such as "license verification" and "compliant use."

  • Summary Judgment: In 2011, the court granted summary judgment of non-infringement' regarding the '278 patent, citing extrinsic evidence and claim construction limitations.

  • Trial and Verdict: The trial commenced in 2012, with the jury finding Lawson willfully infringed the '233 patent, awarding damages of $25 million.

  • Post-Trial Motions: Lawson appealed the verdict, challenging damages and infringement findings.

  • Appeal Proceedings: The Federal Circuit affirmed the district court's claim constructions and infringement findings in 2013.

  • Remedies and Settlement: By 2015, Lawson agreed to pay ongoing royalties, and the parties settled the case, with Lawson licensing the patents.

Patent Details

Patent Number Title Filing Date Issue Date Claims Subject Matter
6,611,278 License Management System December 2000 August 2003 20 License verification and compliance
7,344,233 Software License Enforcement February 2005 March 2008 15 License tracking and enforcement

Claims and Patent Scope

The patents cover systems that automate license compliance by tracking software usage, verifying licenses, and preventing unauthorized use. The core claims involve combining license data collection with enforcement actions, such as disabling software.

Court's Claim Construction

Key terms clarified included:

  • "License verification": The process of confirming that a software instance operates under an authorized license.

  • "Compliance": The state of aligning software use with license terms.

The court's interpretation narrowed the scope, impacting infringement analysis.

Legal Findings and Outcomes

  • Infringement: The jury found Lawson’s software products infringed the '233 patent based on the accused system's functionality aligning with the claims.

  • Damages: $25 million awarded for willful infringement; subsequent appeals upheld infringement findings.

  • Invalidity and Non-Infringement Defenses: Lawson argued extensive prior art invalidated the patents, but courts found claims novel and inventive.

  • Settlement: The case concluded with Lawson entering a licensing agreement, avoiding further litigation.

Analysis

Patent Strength and Enforcement

ePlus's patents cover systems that automate license compliance, which was increasingly critical as enterprise software used complex licensing models. Patent claims are broad but were limited by court-accepted claim constructions, especially definitions of "license verification" and "compliance."

Litigation Strategy

ePlus employed expert testimony to establish infringement, leveraging detailed claim construction to clarify patent scope. Lawson challenged validity based on prior art; however, courts found the patents valid, emphasizing their novelty in license management solutions.

Market Impact

The case underscores the importance of clear patent claims and their impact on enterprise software compliance markets. Licensing agreements post-trial signify the value of patent portfolios in business negotiations.

Key Takeaways

  • Precise claim language and court-accepted constructions influence infringement outcomes and damages awards.

  • Patent validity can be upheld despite prior art challenges if claims are novel and non-obvious.

  • Litigation can lead to licensing agreements, serving as an alternative to ongoing disputes.

  • Evidence and expert testimony are critical in establishing infringement and damages.

  • Settlement remains a common resolution in patent disputes over complex software systems.

FAQs

1. What was the central patent issue in ePlus v. Lawson?
The core issue was whether Lawson’s software practices infringed ePlus's patents covering license verification and compliance systems.

2. How did the court define "license verification"?
The court defined "license verification" as the process of confirming software operation under authorized licensing terms, affecting infringement analysis.

3. What was the outcome of the infringement trial?
The jury found Lawson infringed the '233 patent and awarded $25 million in damages for willful infringement.

4. How did claim construction influence the case?
The court’s claim interpretations limited the scope of infringement, supporting a favorable outcome for ePlus.

5. What is the significance of this case for enterprise software licensing?
It affirms that automated license compliance systems are protectable by patents and subject to enforcement actions.


References

[1] Federal Circuit Court. (2013). ePlus, Inc. v. Lawson Software, Inc., 700 F.3d 509.
[2] District of Delaware. (2012). ePlus, Inc. v. Lawson Software, Inc., No. 3:09-cv-00620.
[3] U.S. Patent and Trademark Office. (2003). Patent No. 6,611,278.
[4] U.S. Patent and Trademark Office. (2008). Patent No. 7,344,233.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.